Rosuvastatin plus fenofibrate in diabetic dyslipidemia: a hospital record based study

K. Madhana Gopal, M. Meganathan, S. Vithiavathi, S. Prabhu Shankar, K. Balamurugan, Deepa Kameswari P.


Background: Cardiovascular diseases (CVD) are the leading cause of death throughout world population each and every year. Focus on dyslipidemia management is urgently required in India to halt the rising tide of CVD. The purpose of diabetic dyslipidemia study is a record based one, to find out the effect of Rosuvastatin plus Fenofibrate, in adult Type 2 diabetes with dyslipidemia, with high TGL/HDL ratio in Lipid profiles, in a tertiary care hospital in the Union territory of Puducherry.

Methods: There were 101 patients hospital records were analysed in which male were 45 and females were 56. The various biochemical parameters like serum Total Cholesterol, HDL, LDL, TGL, Non-HDL, TCL/HDL Ratio and TGL/HDL ratio reports were collected before and after 12-weeks of Rosuvastatin 10 mg with Fenofibrate 145 mg combination, for the treatment period once daily for their lipid-lowering therapy.

Results: The combination therapies of Rosuvastatin plus Fenofibrate were safe and feasible to achieve more TG goal and proved that has predominately decreased the elevated lipid profiles from the medical resources of our record based study. The use of combination medications of rosuvastatin (10mg) plus Fenofibrate (145mg) is often needed to effectively treat the lipid triad, by the potency of rosuvastatin to lower LDL-C and Fenofibrates effectiveness in lowering TG in treating mixed diabetic dyslipidemia.

Conclusions: After Rosuvastatin (10mg) plus Fenofibrate (145mg), the lipid profile data proved that the importance of TGL/HDL ratio apart from the TCL/HDL ratio, for good lipid control in diabetic dyslipidemic patients.


Cardiovascular disease, Diabetic dyslipidemia, Fenofibrates, Rosuvastatin

Full Text:



WHO Cardiovascular diseases. Geneva; 2017. Available at: room/fact-sheets/detail/cardiovascular-diseases- (cvds). Accessed 9 November 2018.

Wilson L, Bhatnagar P, Townsend N. Comparing trends in mortality from cardiovascular disease and cancer in the United Kingdom, 1983-2013: join point regression analysis. Population health metrics. 2017 Dec;15(1):23.

McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. New Eng J Medi. 1971 Dec 23;285(26):1441-6.

Krishnan MN. Coronary heart disease and risk factors in India - On the brink of an epidemic? Indian Heart J. 2012;64:364-7.

Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clinical Medicine Insights: Cardiology. 2012 Jan;6:CMC-S4324.

Chen YP, Chang KC, Tseng WK, Yin WH, Chen JW, Lee YT, et al. Increased rosuvastatin dose versus concomitant fenofibrate and rosuvastatin therapy to achieve lipid goal in patients with diabetes or atherosclerosis with metabolic syndrome. Acta Cardiologica Sinica. 2013 Sep;29(5):421.

A Randomized, Double-Blind, Placebo-Controlled with Active Comparator, 12-Week Study of DS-8500a in Subjects with Type 2 Diabetes Mellitus on Metformin. Clinical study protocol. Clinical Study Report DS8500-A-U202 Version 1.0, 30 Aug 2017 16.1.1 Protocol and Amendments. Daiichi Sankyo, Inc. 399 Thornall Street Edison, NJ 08837 United States.

Baer J. AACE and EAS Lipid Guidelines: - Expert Analysis. J Am Coll Cardiol. Aug 11; 2017. Available at: https: // cardiology/articles/2017/08/11/08/35/aace-and-eas-lipid-guidelines. Accessed 11 September 2018.

Collins P. Risk factors for cardiovascular disease and hormone therapy in women. Heart. 2006 May 1;92(suppl 3):iii24-8.

Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reproductive sciences. 2010 Jun;17(6):511-31.

Strain JD, Farver DK. Clem JR. A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/ fenofibric acid therapy. Clinical Pharmacology: Advances and Applications 2010;2:95-104.

Wankhade PS, Pedhambkar RB, Pagare RS, Pedhambkar BS. Prevalence and risk factors of dyslipidemia among male industrial workers in India. Int J Community Med Public Health. 2018;5:1458-65.

Iyengar S, Puri R, Narasingan S. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016-part 1. J Prac Cardio Scien. 2016 May 1;2(2):134.

Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. A multicenter, double-blind study to compare the efficacy and safety of once daily atorvastatin and aimvastatin in asian people with elevated LDL cholesterol. Result from ASIA study. J Formos Med Assoc. 2002;101:478-87.

Sponder M, Fritzer-Szekeres M, Marculescu R, Litschauer B, Strametz-Juranek J. A new coronary artery disease grading system correlates with numerous routine parameters that were associated with atherosclerosis: a grading system for coronary artery disease severity. Vasc Health Risk Manag. 2014;10:641-7.

Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.

Dixit R, Jagan S. Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia. Int J Pharmacol Clin Scien. Mar 2016;5:25-31.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.

NCEP Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;16:2486-97.